(Bloomberg) -- US regulators approved updated versions of the Covid-19 vaccines made by Pfizer Inc. and Moderna ... While ...

“Samples were sparse, the TV ads were late, and they were too benign and not exciting.” Rubin also believes Pfizer did not chase the right market. “They did not court the nurses, the ...

Valneva and Pfizer have reported positive data from a Phase II trial of a second booster dose of their Lyme disease vaccine ...

Pfizer has agreed to settle more than 10,000 ... the market after a cancer-causing substance called NDMA was found in samples ...

The Pfizer/BioNTech vaccine can still target a ... and one without the mutation - and then bathed those viruses in blood samples taken from 20 patients that had been vaccinated in clinical trials.

With the flu season imminent, new COVID-19 and influenza vaccines are available. What’s new with the vaccines and when should ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

by researchers at Pfizer Research and Development, that detailed their use of the high-plex SomaScan ® Assay, leveraging an ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...